港股異動 | 諾輝健康(6606.HK)漲近9% 料2021年營收和毛利率同比大增
格隆匯1月17日丨諾輝健康(6606.HK)高開高走,現漲幅擴大至8.81%,現報22.96港元,總市值98億港元。上週五公吿,公司預期2021年收入總額為2.05億-2.17億元,同比增長了190.8%至207.8%;毛利約1.47億-1.58億元,同比增長了294.6%至 324.2%。收入總額及毛利增加主要是因為公司的產品(即常衞清及噗噗管)的收入及毛利增加,從而使得收入總額大幅增加。此外,公司“驗孕棒式”幽門螺桿菌自測產品日前上市,年產能1500萬份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.